

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1 53(b))

Attorney Docket No. PP16090.004 (35784/235886)

First Inventor or Application Identifier: Whitehouse

Title of Invention: METHODS AND COMPOSITIONS FOR THE TREATMENT OF PERIPHERAL ARTERY DISEASE

Express Mail Label No. EM166865535US

6-22-0

ADDRESS TO: BOX PATENT APPLICATION
COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Transmitted herewith for filing in the United States Patent Office is a patent application for:

Inventor:

Martha Jo Whitehouse

151 Upper Terrace

San Francisco, CA 94117

Assignee of this invention is Chiron Corporation

1.	$\boxtimes$	The Filing Fee has been calculated as	shown below:
2.	П	Applicant claims Small Entity Status.	See 37 CFR 1.27.

	No. Filed	No. Extra	Small Rate	Entity Fee 0	Large Rate	Entity Fee 1
BASIC FEE	110. Flict	No. Latta	Katt	\$0	Rate	\$ 710
TOTAL CLAIMS:	82 - 20 =	62	X 9	= \$0	x 18	= \$1,116
INDEP CLAIMS:	4 - 3 =	1	X 40	) = \$0	x 80	= \$ 80
[□]MULTIPLE DEPEN PRESENTED	+135 = \$		+270	= \$		
*If the difference in Colu enter "0" in Column 2	TOTAL \$		TOTAL	L \$1,906		

The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Acct. No.

a.	Ш	Fees	required	l under	· 37	CFR	1.16	(Na	tional	filing	fees)	)
4		-			~-	~=~		~ -				

- b. Eees required under 37 CFR 1.17 (National application processing fees).
- A check in the amount of \$\\$ for the filing fee is enclosed.
- The above filing fee will be paid along with Applicant(s) Response to the Notice to File Missing Parts.
- 3. Specification; Total Pages 74
- 4. \(\simega\) Sheets of Formal Drawing(s) (35 USC 113)
- 5. Declaration and Power of Attorney; [Total Pages \_\_\_]
  - a. Newly executed (original or copy)
    - b. Copy from a prior application (37 CFR 1.63(d))

(for continuation/divisional with Box 18 completed)

- i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) & 1.33(b).
- 6. Application Data Sheet. See 37 CFR 1.76

7. 8.	CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)  Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)									
	a.	$\boxtimes$	Computer Readable Co	py (CRF)						
	b.	ليا	Request for Transfer of under 37 CFR § 1.821(	Computer Readable Form of Sequence Listing						
	c.	$\boxtimes$	Specification Sequence	•						
	d.	$\boxtimes$	ii. Paper (6 P Statement verifying ide	Pages)						
ACC	OMPAN	YING A	PPLICATION PARTS							
9.		Assign	Assignment Papers (cover sheet & document(s) (including a check for the \$40.00 fee)							
10.		37 CF	R 3.73(b) Statement (when	n there is an assignee); Dewer of Attorney						
11.		Englis	h Translation Document (	if applicable)						
12.		Inform	nation Disclosure Statemer	nt (IDS)/PTO-1449; Copies of IDS Citations						
13.		Prelim	ninary Amendment							
14.	$\boxtimes$	Return	Receipt Postcard (MPEP	503) (Should be specifically itemized)						
15.			Certified Copy of Priority Document(s) (if foreign priority is claimed) Foreign Priority is							
16.		Request and Certification for Non-publication under 35 U.S.C. 122(b)(2)(B)(i).  Applicant must attach form PTO/SB35 or its equivalent.								
17.		Reque	Request for Early Publication Under 37 CFR § 1.219. Fee of \$300.00 is enclosed.							
18.	If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CF 1.76:  Continuation Divisional Continuation in Part (CIP)									
		of pric	or Application No:; Fi	led						
	Prior Application Information: Exa			niner Group/Art Unit:						
under E	30x 5b, is c	onsidered a	part of the disclosure of the acco	e disclosure of the prior application, from which an oath or declaration is supplied ompanying continuation or divisional application and is hereby incorporated by portion has been inadvertently omitted from the submitted application parts.						
19.	19. CORRESPONDENCE ADDRESS									
	Chiron Corporation Intellectual Property Department P.O. Box 8097 Emeryville, CA 94662-8097 Tel. (510) 655-8730 Fax (510) 655-3542									
Signa		estir"	T. Hen	,						
		rd: Leslie ition No.	e T. Henry 8							
	Alston & Bird LLP			"Express Mail" mailing label number EM166865535US						
	of Ameri		G : 4000	Date of Deposit June 21, 2001						
	-	on Street, 28280-400	Suite 4000 00	I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR						
Tel F	Raleigh Of	ffice (919)		1.10 on the date indicated above and is addressed to Box Patent Application, Commissioner For Patents, Washington, DC 20231.						
RTA	01/209840	6v1		Polly P. Burton Polly P. Byron						

### 

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Whitehouse

Appl. No.:

Not yet assigned

Filed: For:

June 21, 2001 METHODS AND COMPOSITIONS FOR THE TREATMENT

OF PERIPHERAL ARTERY DISEASE

## STATEMENT IN SUPPORT OF FILING A SEQUENCE LISTING UNDER 37 CFR § 1.821(f)

Commissioner for Patents Washington, DC 20231

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted concurrently herewith in accordance with 37 CFR § 1.821(c) and (e), are the same.

Respectfully submitted,

LeliT, Henry

Leslie T. Henry

Agent for Applicant Registration No. 45,714

### Alston & Bird LLP

Bank of America Plaza 101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 Tel Raleigh Office (919) 420-2200 Fax Raleigh Office (919) 420-2260

"Express Mail" Mailing Label Number EM166865535US Date of Deposit: June 21, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Commissioner for Patents, Washington, DC 20231.

Pally 4, Button
Polly P. Button

### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Washington, DC 20231, on